CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 86 enrolled
Drug / intervention
Mirtazapine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00249444
NCT00249444Phase 2Completed
CompareCT.gov

A Placebo Controlled Trial of Mirtazapine for Patients With Depression and Cocaine Dependence

New York State Psychiatric Institute·interventional·Posted Nov 7, 2005·Updated Oct 25, 2017

In Brief

A Phase 2 clinical trial evaluating Mirtazapine and Placebo for Cocaine Dependence and Depression. Completed, enrolled 86 participants across 1 site.

Detailed Summary

Many substance dependent individuals also suffer from depression. Past research suggests that antidepressant medication is helpful in treating such individuals. This study will determine the effectiveness of mirtazapine, an antidepressant medication, in treating cocaine dependent individuals who also suffer from depression. This study includes free treatment for cocaine dependence that includes medication and a behavioral intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence, Depression
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 7, 2005
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 20.7 years ago

Interventions

Mirtazapinedrug

Mirtazapine

Placebodrug

placebo